Beyond The Burden &

Challenges of Overactive
Bladder
Advisory Board
21 SEPTEMBER 2019
 st
1 Session

OAB Epidemiology ( Focusing on Each Subgroups ) and Its

Update Management Therapy in Indonesia.
 st
1 Session

Topic Discussion : Epidemiology Data

What are your thoughts on the OAB epidemiology data just
presented?
What factors that affects the percentage in each subgroups of
OAB epidemiology ?
 What is the awareness of OAB
in your from your perspec ves ?
What are the reasons for the low awareness of OAB?
What is the most bothersome OAB symptoms that caused
pa ents to visit your clinic / hospital ?
What is the most bothersome condi on ( Produc vity, sexual
func on, cannot sleep … etc ) which reduce QOL pa ents and
caused them to visit your clinic / hospital ?
Is there any QoL issue related to OAB that we can bring to
increase the awareness? If yes, please explain.
What is your plan a er you see this OAB epidemiology data ?
 What is your expecta on
for the next OAB epidemiology data ?
 st
1 Session

Topic Discussion : Management Therapy

Is there any different implementa on between the guideline
and daily clinical prac ce?
What treatment op ons are available for managing OAB in
your hospital / clinic ?
What is the most important factor when deciding which
treatment to use?
How do you feel that the diagnosis and management of OAB
can be improved ?
What an muscarinics are most frequently used in your
hospital / clinics ?
Based on your perspec ve, when do you use an muscarinics
or Mirabegron (B3 agonist)?
In Indonesia, do clinicians typically use an muscarinics in
combina on with each other?
What do you think about using the solifenacin-mirabegron
combina on in your prac ce?
For which subset of pa ents would the solifenacin-
mirabegron combina on be most suitable?
What kind of educa on that you give to the pa ents during
their visit related to OAB Therapy?
 nd
2 Session

Persistence and Adherence in OAB management

What are your thoughts on the study data just presented?
How important are persistence and adherence in your
perspec ve to OAB therapy?
How long have you ever treated OAB in one pa ents ?
What factors that affect persistence and adherence during
OAB treatment ?
In Indonesia, what do you do to to make the OAB pa ents
comply and persist to the therapy ?
Will the Believe and related studies help convince clinicians to
use Mirabegron for first line therapy for OAB ?
What factors that determine the successful of OAB therapy ?
 rd
3 Session

Mirabegron Safety and Long-term Study

What are your thoughts on the study data just presented?
Will the results of these studies help convince clinicians to
use mirabegron for their pa ents with OAB?
What side effects that become your main concern when you
treat OAB pa ents with Mirabegron? And why ?
What side effects are most frequently complained by pa ents
with these agents?
How do you typically address these side effects?
How important an cholinergic burden (ACB) side effects in
your perspec ve ?
What kind of special popula on of pa ents that needs extra
a en on regarding the ACB side effects?
What will you do if OAB pa ent comes with ACB side effect ?
Will you stop the treatment, reduce the dose
or switching to other treatments?
 The concept of using mirabegron in place of an
an muscarinic – do you think that this is a sensible approach?
What further data do you require to support your future use
of mirabegron?
Final Conclusion